In conclusion, our data demonstrate for the first time that Gefitinib in combination PA-MSHA promotes anti-proliferation, cell cycle redistribution, apoptosis inducement via caspase family proteins, and inhibition of EGFR signal pathway effects in different genotypic NSCLC cells, and especially in EGFR-TKI-resistant (A549 and NCI-H1975) cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.